Skip to main content

[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” comments=”off” featured_image=”off” _builder_version=”4.16″ _module_preset=”default” title_level=”h6″ custom_padding=”||20px||false|false” global_colors_info=”{}”][/et_pb_post_title][et_pb_text _builder_version=”4.16″ _module_preset=”default” animation_style=”fade” global_colors_info=”{}”]

Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be launched in Nigeria in association with our local distributor, Bolar Pharmaceuticals. Nigeria is one of the most populous nations in Africa, and has recently faced an increasing prevalence of stroke (>250,000 in 2015*) and other cardiovascular diseases. NeuroAiD is bringing a unique evidence-based therapeutic opportunity for the victims to recover faster and better.

*Global Burden Disease 2015 data

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]